<DOC>
	<DOCNO>NCT01319019</DOCNO>
	<brief_summary>This study primarily design assess dose response , dose interval , efficacy safety three daily ( QD ) dose ( 100mcg , 400mcg 800mcg ) three twice daily ( BID ) dose ( 100mcg , 200mcg 400mcg , ) GSK961081 administer via DISKUS™ 28 day subject moderate/severe COPD versus placebo . Salmeterol 50mcg BID include study active comparator .</brief_summary>
	<brief_title>A 4-week Dose-Ranging , Dose-Interval , Efficacy , Safety Tolerability Study GSK961081 Subjects With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>This phase IIb multicentre , randomise , double-blind , double-dummy , placebo- active-controlled , parallel-group , dose-ranging dose-interval study . Eligible subject enter seven-day run-in period follow 28 day double-blind , double-dummy treatment via DISKUS inhaler . The study consist 8 visit , mainly conduct outpatient basis , 6 clinic visit 2 phone contact , include post-treatment visit follow adverse event . There approximately 425 subject randomise study .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Outpatient Subjects Subjects give sign date informed consent participate 40 year age , inclusive , Visit 1 Male female Subjects establish clinical history COPD Current previous cigarette smoker history ≥ 10 packyears cigarette smoke Subjects follow liver function test value : Subjects measure postsalbutamol FEV1/FVC ratio &lt; 0.70 Visit 1 ( Screening ) . Subjects measure postsalbutamol FEV1 3070 % predict normal value Women pregnant lactate plan become pregnant study . Current diagnosis asthma Other significant respiratory disorder besides COPD , include alpha1 deficiency Previous lung resection surgery Significant abnormalities chest xray presentation Hospitalization COPD exacerbation within 12 week prior screen Use oral corticosteroid antibiotic COPD antibiotic low respiratory tract infection within 6 week Any significant disease would put subject risk study participation BMI great 35 Pacemaker Significantly abnormal ECG , clinical lab finding ( include Hepatitis B C ) Cancer Allergy hypersensitivity beta adrenergic receptoragonist , sympathomimetic , anticholinergic/antimuscarinic receptor antagonist , inhaler excipients Diseases would contraindicate use anticholinergic Use sysemic corticosteroid within 6 week screen Use longacting betaagonists within 48 hour screen Use tiotropium within 7 day screen Use theophylline antileukotrienes within 48 hour screen Use shortacting bronchodilator within 4 hour screen Use investigational medicine within 30 day screen Use high dose inhale corticosteroid Use longterm oxygen therapy , CPAP NIPPV Participation acute phase pulmonary rehabilitation program within 4 week prior Visit 1 Regular ( q.i.d great ) use short acting bronchodilator , include nebulized therapy Affiliation Investigator Site Questionable Validity Consent Previous use GSK961081</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>lung function</keyword>
	<keyword>bronchodilator</keyword>
	<keyword>COPD , dose response , dose interval , efficacy , safety , PD , PK</keyword>
</DOC>